Top Markets
Coin of the day
TaiRx, Inc. TaiRx, Inc.

TaiRx, Inc.

6580
Rank in Stocks #25983
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a... TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
Share Price
$0.39430795
Market Cap
$44.21M
Change (1 day)
-3.50%
Change (1 year)
-46.97%
Country
TW
Trade TaiRx, Inc. (6580)

Category

Earnings for TaiRx, Inc. (6580)
Earnings in 2026 TTM: 0
According to TaiRx, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for TaiRx, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
$-3.09B -
US